As of Nov 19, 2026, 1 of 1 active firms rate ONCY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ONCY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.07 – $-0.06 · 2 analysts · -42% YoY
Next period, 2 analysts expect Oncolytics Biotech Inc to earn $-0.06 a share (range $-0.07 – $-0.06), versus $-0.11 a year earlier. Full-year consensus is $-0.38, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oncolytics Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ONCY.
#1
DM
Douglas Miehm
RBC Capital · Rank #263
Buy
$3.50+705.3% to target
Overall win rate
43%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$5.00+1050.5% to target
Overall win rate
36%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$3.00+590.3% to target
Overall win rate
30%
+ Follow
#4
DL
Douglas Loe
Leede Financial
Buy
$4.00+820.4% to target
Coverage
—
+ Follow
#5
CM
Chad Messer
Lake Street
Buy
$7.00+1510.7% to target
Coverage
—
+ Follow
ONCY stock forecast FAQ
What is ONCY's average 12-month price target?+
The 1 active firms with a live target average $5.00 for Oncolytics Biotech Inc over the next 12 months, ranging from a $5.00 high to a $5.00 low, as of Nov 19, 2026.
Is ONCY stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ONCY?+
1 active firms have a recognized rating on Oncolytics Biotech Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ONCY?+
Among analysts who currently cover ONCY, Douglas Miehm of RBC Capital has the strongest overall Quantellect track record (Rank #263). Their current call is Buy with a $3.50 target.
What is Oncolytics Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.07 – $-0.06) across 2 analysts. Full-year EPS is projected at $-0.38, rising to $-0.28 the following year.
How much revenue is Oncolytics Biotech Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ONCY lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ONCY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ONCY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.